Exagen
XGN
33 hedge funds and large institutions have $19.7M invested in Exagen in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 2 closing their positions.
1,300% more call options, than puts
Call options by funds: $14K | Put options by funds: $1K
72% more capital invested
Capital invested by funds: $11.4M → $19.7M (+$8.28M)
0.51% more ownership
Funds ownership: 36.19% → 36.7% (+0.51%)
0% more funds holding
Funds holding: 33 → 33 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$455K |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$241K |
| 3 |
Renaissance Technologies
New York
|
+$211K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$92K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$41.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$705K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$89.3K |
| 3 |
BlackRock
New York
|
-$26.3K |
| 4 |
PM
Penbrook Management
New York
|
-$16.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.9K |
XGN Hedge Fund Activity: Q3 2024 in Review
33 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q3 2024, worth a combined $19.7M — up 72% from $11.4M a quarter earlier.
Fund positioning in XGN was balanced in Q3 2024: 2 funds opened new positions, 2 closed out, 9 added to existing stakes and 9 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $455K. The largest seller was Wasatch Advisors, cutting an estimated $705K.
- 33 institutional investors held Exagen (XGN) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $19.7M of Exagen stock for Q3 2024, up 72% quarter-over-quarter.
- 2 funds opened new Exagen positions in Q3 2024 and 2 closed out, a net change of 0 holders.
- The largest Exagen buyer in Q3 2024 was Stonepine Capital Management, an estimated $455K added.
- The largest Exagen seller in Q3 2024 was Wasatch Advisors, an estimated $705K sold.
Based on aggregated 13F filings for Q3 2024.